Innate Pharma SA
XBER:IDD
Innate Pharma SA
XBER:IDD
Price:
1.576
EUR
Market Cap:
€213.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Innate Pharma SA
XBER:IDD
|
FR |
|
CSSC Hong Kong Shipping Co Ltd
F:3LL
|
HK |
|
O
|
Outlook Therapeutics Inc
F:41ON
|
US |
|
S
|
Scotts Miracle-Gro Co
F:SCQA
|
US |
|
Electrocomponents PLC
F:ECN
|
UK |
|
A
|
Aspo Oyj
F:ZYD
|
FI |
|
Tencent Music Entertainment Group
OTC:TCMEF
|
CN |
|
P
|
Petroleo Brasileiro SA Petrobras
MAD:XPBRA
|
BR |
|
V
|
Volatus Aerospace Inc
DUS:ABB
|
CA |
|
Country Garden Services Holdings Co Ltd
F:75H
|
CN |
Wall St Price Targets
IDD Price Targets Summary
Innate Pharma SA
Innate Pharma SA
Wall Street analysts forecast IDD stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for IDD is 5.534 EUR with a low forecast of 4.609 EUR and a high forecast of 6.602 EUR.
Lowest Forecast
Price Target
4.609
EUR
192% Upside
Average Forecast
Price Target
5.534
EUR
251% Upside
Highest Forecast
Price Target
6.602
EUR
319% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IDD's stock price target?
Price Target
5.534
EUR
5.534
EUR
According to Wall Street analysts, the average 1-year price target for IDD is 5.534 EUR with a low forecast of 4.609 EUR and a high forecast of 6.602 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
